SOURCE: Medpace


January 06, 2011 09:00 ET

Medpace Announces the Addition of Dr. Jon Bruss, Medical Director, Adding Therapeutic Expertise in Infectious Disease, Antibiotics, Anti-Virals, Vaccines, and Pediatric Medicines

CINCINNATI, OH--(Marketwire - January 6, 2011) - Medpace, Inc. today announced the addition of Jon Bruss, MD, MSPH, MBA, FAAP, FIDSA as a Medical Director with therapeutic expertise in guiding global clinical trials in infectious disease. Dr. Bruss will combine therapeutic experience with existing Medpace clinical trial teams excellence to bring innovative anti-infective drugs to market in partnership with our sponsors.

"Dr. Jon Bruss strengthens the Medpace position supporting our sponsors who are advancing new drugs for infectious disease and vaccines, one of the largest pharmaceutical pipelines for development by biopharmaceutical sponsors," said Jonathan Isaacsohn, MD, FACC, Executive Vice President, Medpace. "Dr. Bruss's experience and industry knowledge will allow us to provide strategic consultation to our sponsors in designing innovative clinical trial methods for many of our customers engaged in bringing new drugs to market in this challenging therapeutic area."

Dr. Jon Bruss has spent 20 years in drug development with global, clinical and regulatory expertise, managing clinical trials in the area of infectious diseases, including leading drug development in the US, Europe, and Asia. His clinical development experience includes the first in novel classes of compounds, involving adults, the elderly, children, and neonates. Dr. Bruss has held positions of increasing responsibility, including Chief Medical Officer, in both large and small pharmaceutical companies. He has also served as a consultant to numerous small biotechnology and large pharmaceutical companies. In addition, his clinical and academic research experience has included infectious disease research, vaccine research, public health management and tuberculosis control.

Dr. Bruss received his Doctor of Medicine degree from the University of New Mexico, School of Medicine and his undergraduate degree in Biology from the University of Utah. He completed his Internship and Residency in pediatrics at the Children's Hospital of New Mexico and Clinical and Research Fellowships in Infectious Diseases at Harvard Medical School. In addition, he earned a Master of Business Administration at Northwestern University - Kellogg School of Management and a Master of Science in Public Health from Tulane University. 

Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services. In June 2009 Medpace was rated as the best CRO by U.S. Investigators in the 2009 CenterWatch Site Survey.

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.

Visit the Medpace website at 

Contact Information